Tiresias - The Raod Ahead

"Why," said the Dodo, "the best way to explain it is to do it."

Lewis Carroll, Alice in Wonderland

My friends,

In the last several epistles Tiresias has talked of management changes, the price action, the motivations and possible mechanics of the management changes, the possible overhang and destiny some stock held by the probably weak or disgruntled hands of members of the previous management. It is now apparent, from the price action and sales of stock, that there was no benevolent Isaac Barrow in the previous management. There does appear to be some selling. Does this concern Tiresias? Should this concern him or his friends. Not in the least. Let the weak hands drop the stock. Let the strong hands take them on, and sooner the better. Tiresias might comment on this in future missives, but suffice it to say, he is not concerned.

Tiresias’s interest is the upcoming AGM, the new CEO report, and the state of play in the various studies.

In no specific order Tiresias is looking to these areas.

1. Carl Zeiss and the introduction of confocal endomicroscopy in in-vivo neurosurgery for malignant brain tumour. Carl Zeiss have been going about this in their slow thorough Teutonic methodical way. If Tiresias would wish something from Carl Zeiss, remembering the nature of Carl Zeiss, and remembering they will be anything but spectacular in any announcement, Tiresias would wish for announcement placement of the CONVIVO end microscopes in more leading neurosurgical units and at least one or two of them in Australia.

2. FDA approval for oral surgery. Tiresias despaired at the slow pace of this, but realistically, he can’t be too critical and has to give some leeway to the previous management, given the pandemic debacle, particularly the two-year Andrews-Victorian hiatus which has slowed everything down. Tiresias expects that the data for this is going to be available shortly and surely the FDA approval is only a matter of crossing the “t’s” and dotting the “I’s”. A foregone conclusion and only a matter of FDA apparatchiks signing a few forms.

3. Breast cancer. We know that the breast-cancer study recruitment in Melbourne is complete, and we now are awaiting the results. Tiresias expects that this will be soon. Tiresias is certain that the results will be exceptional and that the field will be clear for introduction of confocal microscopy to replace frozen section biopsy in breast cancer and all cancer surgery. Naturally there are bureaucratic hurdles and other pecuniary interest in the way, but Tiresias is sure that the new management will efficiently negotiate all these. Towards this, recruitment of leading breast surgeons and galvanising patient groups will be essential to progress this quickly and avoid it being further mired in the bureaucratic nightmare that Australian medicine has become.

4. Head and neck surgery. This is the obvious next from the oral cancer surgery and to reduce the huge mortality and disfiguring commando procedures that are carried out now by head and neck surgeons blind to the presence of cancer cells in their enormous surgical fields.

5. Other areas;

Tiresias will address these further as the year progresses, but he would just like to reiterate several prime targets, which the previous management seemed to ignore.

Again, in no particular order;

a) Skin cancer, and specifically Mohs surgery

b) Gastrointestinal

c) Cervical Cancer

d) Urology

Let this new lap around the Sun be a good one.